Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 05 Jul 2017 Status changed from recruiting to suspended.
- 25 May 2016 Planned primary completion date changed from 1 Oct 2018 to 1 May 2018.
- 25 May 2016 Status changed from not yet recruiting to recruiting.